Recursion Pharmaceuticals
RXRX
RXRX
158 hedge funds and large institutions have $953M invested in Recursion Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 58 increasing their positions, 43 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
0.32% more ownership
Funds ownership: 68.76% → 69.08% (+0.32%)
0% more funds holding
Funds holding: 158 → 158 (0)
0% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 26
Holders
158
Holding in Top 10
6
Calls
$1.04M
Puts
$765K
Top Buyers
| 1 | +$20.6M | |
| 2 | +$8.77M | |
| 3 | +$8.68M | |
| 4 |
BlackRock
New York
|
+$7.38M |
| 5 |
LIM
Lingotto Investment Management
London,
United Kingdom
|
+$5.79M |
Top Sellers
| 1 | -$12.3M | |
| 2 | -$10.2M | |
| 3 | -$5.04M | |
| 4 |
HMC
Harvard Management Company
Boston,
Massachusetts
|
-$4.68M |
| 5 |
Millennium Management
New York
|
-$4.31M |